A binary star system in the centre of the Milky Way provides new clues as to how stars form around the central black hole

New research has shown how the quantum mechanical principle of strong coupling opens unrivalled possibilities for designing optical filters: So-called ‘polariton filters’ break new ground in imaging. Publication in ‘Nature Communications’

Prestigious research grant awarded to the project about the stability and decline of elite economic and political power. Up to two million euros over five years

Researchers at the University of Cologne’s CEPLAS Cluster of Excellence on Plant Sciences have identified two fungal enzymes that hijack the immune system of plants, playing a critical role in the colonization of plant roots. These findings open new avenues for interventions in both medicine and agriculture / publication in ‘Cell Host & Microbe’

Constant ‘churn’ of new cancer cells gives the disease ample room for evolutionary innovation, according to a study in the journal eLIFE

The German Research Foundation (DFG) has extended the funding of two Collaborative Research Centres (CRC) in the fields of linguistics and neuroscience

Annual ranking of ‘Highly Cited Researchers’ published as an indicator for outstanding research / University of Cologne represented by three biologists and five medical researchers

The Hub focuses on the relationships between human health, climate protection and the conservation of biodiversity / The University of Cologne cooperates with international partners such as the Club of Rome, Princeton University and other academic institutions

Researchers at the University of Cologne develop three-dimensional mathematical model of prostate cancer. The model depicts various processes, including tumour growth, genetic evolution and tumour cell competition. It may also be applicable to other forms of cancer

An international research consortium from Cologne, London, Vienna, Heidelberg, Zaragoza and Madrid have tested a novel therapeutic concept to treat virus-induced lung failure in patients with severe COVID-19 in a phase 2 clinical trial. The approach may also be applicable to other infections